Catalyst Event
InnoCare Pharma Ltd (9969) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
4/27/2026, 12:00:00 AM
Announced on 2026-04-27 that study results for Mesutoclax and Orelabrutinib were accepted for the 2026 ASCO Annual Meeting, with Mesutoclax selected for oral presentation. Medium importance estimated as an oral presentation at a major conference is likely to cause ≥5% price impact.
Korean Translation
2026년 4월 27일, 메소토클락스 및 오렐라브루티닙 연구 결과가 2026년 ASCO 연례회의 발표 대상으로 채택되었으며 메소토클락스가 구두 발표로 선정되었음을 발표함. 주요 학회 구두 발표 선정은 5% 이상의 주가 변동을 유발할 수 있어 중요도를 'Medium'으로 평가함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the 2025 final cash dividend of RMB 14.3 per 10 shares, with payment on July 13, 2026, scheduled. This consistent dividend payout is estimated to have a minor positive impact on investor sentiment.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date for a proposed final dividend of HK$0.169 per share for the year ended December 31, 2025, on 2026-06-12 scheduled. Low importance as dividend ex-dates typically result in minor price adjustments.
6/12/2026, 12:00:00 AM
Hangzhou Tigermed Consulting Co Ltd (3347) · Other
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
6/2/2026, 12:00:00 AM
GRAIL Inc (GRAL) · Other
GRAIL to present additional data from the NHS-Galleri trial at the 2026 ASCO Annual Meeting on May 30, 2026, scheduled. High importance estimated as clinical data is a key valuation driver.
5/30/2026, 12:00:00 AM
ANTA Sports Products Limited (2020) · Other
Ex-dividend date for the final FY2025 dividend of HK$1.08 per share is scheduled for May 15, 2026.
5/15/2026, 12:00:00 AM